首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
【24h】

A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.

机译:拟议分数,用于预测化疗引起的发热性中性粒细胞减少症患儿的严重感染并发症。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Febrile neutropenia (FN) is one of most common complications in patients with cancer during chemotherapy. Identifying factors associated with severe infectious complications (SICs) at time of admission for fever and neutropenia is necessary for better treatment. PROCEDURE: We revised all medical charts of patients under 18 years old who developed a first episode of FN present from January 2000 to December 2003. Criteria for a SIC were defined. These included the presence of bacteremia or fungemia, sepsis, septic shock, and/or death from infection. To identify risk factors SIC was associated with the first FN episode. RESULTS: Factors identified in univariate analysis were female sex, age less than 5 years old, acute myeloid leukemia, baseline disease activity, use of central venous catheter, hemoglobin level < 7 g/dL, leukocytes count < 500 cells/mm(3), granulocytes count < 500 cells/mm(3), monocytes count < 100 cells/mm(3), platelets < 20,000, and body temperature > 38.5 degrees C, a chemotherapy interval < 7 days, presence of mucositis, pneumonia, absence of upper respiratory tract infection, or the presence of any clinical focus on first physical examination. In multivariate analysis the variables that remained as independent predictive risk factors for SIC were age less than 5 years, use of central venous catheter, body temperature > 38.5 degrees C, hemoglobin level < 7 g/dL, any clinical focus of infection on first examination and absence of upper respiratory tract infection. The FN population was than divided among 3 different risk groups as follows: group 1 (low risk), group 2 (intermediate risk), with a 13 (4.4 to 38.3)-fold risk for SIC; and group 3 (high risk) with a 50 (16.4 to 149.2)-fold risk for SIC. CONCLUSIONS: This study suggests that patients with FN can be stratified for risk of SIC using clinical parameters at hospital admission.
机译:背景:发热性中性粒细胞减少症(FN)是癌症化疗期间最常见的并发症之一。为了更好地治疗,必须确定与发热和中性粒细胞减少症入院时的严重感染并发症(SIC)相关的因素。程序:我们修订了2000年1月至2003年12月出现FN的首发的18岁以下患者的所有病历。确定了SIC的标准。其中包括菌血症或真菌病,败血症,败血性休克和/或感染死亡。为了确定危险因素,SIC与第一次FN发作相关。结果:单因素分析确定的因素是女性,年龄小于5岁,急性髓性白血病,基线疾病活动,使用中央静脉导管,血红蛋白水平<7 g / dL,白细胞计数<500细胞/ mm(3) ,粒细胞计数<500细胞/ mm(3),单核细胞计数<100细胞/ mm(3),血小板<20,000和体温> 38.5摄氏度,化学疗法间隔<7天,是否存在粘膜炎,肺炎,是否存在上呼吸道感染或任何临床检查都集中在首次体检上。在多变量分析中,仍然作为SIC的独立预测危险因素的变量是年龄小于5岁,使用中心静脉导管,体温> 38.5摄氏度,血红蛋白水平<7 g / dL,任何临床感染的重点是首次检查没有上呼吸道感染。 FN人群按以下方式分为3个不同的风险组:第1组(低风险),第2组(中度风险),SIC的风险是13倍(4.4至38.3)倍;第3组(高风险)患SIC的风险是50倍(16.4至149.2)倍。结论:这项研究表明,可以使用入院时的临床参数对FN患者进行SIC风险分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号